How to Prevent Pharmacy Diversion Effectively

A pharmacy can reconcile to the penny and still have a diversion problem. The gap is often not a missing inventory count. It is a control failure: an unresolved discrepancy, an override no one reviews, a return process with weak documentation, or an employee who understands where accountability ends. Knowing how to prevent pharmacy diversion requires more than a policy binder. It requires daily operating controls that make irregular activity visible, assign ownership, and produce records that can withstand scrutiny.

Diversion prevention is not limited to employee theft. Controlled substances may be diverted through fraudulent prescriptions, forged or altered orders, prescription transfers, inventory manipulation, fraudulent waste or disposal activity, customer theft, and vendor-related weaknesses. A sound program recognizes that different risks leave different operational signals.

Why Diversion Prevention Matters

Diversion can expose a pharmacy to DEA investigations, administrative action, financial loss, reputational damage, and potential criminal liability. While every pharmacy faces different risks, most diversion events share one thing in common: a breakdown in internal controls what went unnoticed or unresolved.

How to Prevent Pharmacy Diversion With Layered Controls

No single safeguard prevents diversion. Perpetual inventory systems, cameras, automation, prescription drug monitoring program reviews, and employee screening all have value, but none is sufficient in isolation. Effective diversion prevention depends on layers of controls that reinforce one another.

Start with a written controlled substance accountability program tailored to the pharmacy's operations. The program should identify who is responsible for ordering, receiving, storage, dispensing, reconciliation, discrepancy review, reporting, record retention, and escalation. Job titles alone are not enough. Each responsibility needs a designated owner, a backup, and a clear timeframe for action.

This is where many pharmacies create unnecessary exposure. A policy may state that discrepancies must be investigated, but it does not define what qualifies as a discrepancy, who opens the investigation, how findings are documented, or when leadership and legal counsel are notified. Broad language leaves room for inconsistent decisions. Consistency is a major factor in demonstrating that a compliance program is functioning as intended.

Physical security should match the substance, the volume handled, and the pharmacy's risk profile. Restricted access to controlled substance areas is foundational, but access alone should not be treated as accountability. Limit keys, codes, alarm access, safe combinations, and system permissions to individuals with a legitimate operational need. Review those permissions when duties change, during leave periods, and immediately upon separation.

For many pharmacies, the most meaningful physical controls include secure storage, monitored access points, camera coverage that supports investigations, and procedures for deliveries, returns, transfers, and waste. Camera systems are useful only when recordings are retained for an appropriate period, timestamps are reliable, and management knows how to retrieve footage when an issue arises.

Build accountability into receiving and inventory movement

Controlled substances are vulnerable at every handoff. Receiving is not merely a clerical function. The person accepting a shipment should verify the shipment against the order and invoice, document shortages or overages promptly, and secure product before moving to another task. When one employee orders, receives, adjusts inventory, and reconciles discrepancies without meaningful review, the pharmacy has created a preventable concentration of control.

Segregation of duties should be practical rather than theoretical. A small independent pharmacy may not have enough personnel to fully separate each function. In that case, the owner or pharmacist-in-charge can introduce compensating controls, such as independent review of invoices, random recounts, periodic owner review of adjustments, and documented reconciliation of high-risk products. The question is not whether a pharmacy can copy a large chain's process. The question is whether it can demonstrate reliable oversight with the resources it has.

Pay particular attention to inventory adjustments. Each adjustment should have a stated reason, supporting documentation, date, quantity, product identifier, and approval or review trail. Vague entries such as “count correction” or “system issue” are not meaningful explanations when they recur. Trend data matters. A series of small adjustments can be more revealing than one obvious loss.

Treat Reconciliation as an Investigation Tool

Reconciliation should do more than confirm that numbers match. It should identify where a controlled substance entered the pharmacy, where it was stored, how it was dispensed or transferred, and why any variance occurred. The closer reconciliation occurs to the transaction, the more likely the pharmacy can determine what happened.

High-risk medications, unusual dosage forms, frequent shortages, and products with a history of discrepancies may warrant more frequent counts than the minimum operational cadence. A risk-based schedule is often more defensible than treating every product identically. Frequency should be supported by documented reasoning and adjusted when the pharmacy's risk changes.

When a discrepancy is found, avoid the temptation to simply recount until the records align. A recount may be appropriate, but it is the beginning of the review, not the end. The pharmacy should determine whether the variance relates to receiving, dispensing, returns, transfers, dispensing system activity, inventory adjustments, waste, theft, or a documentation error.

A documented discrepancy review should generally capture the following:

• The medication, quantity, date discovered, and persons involved in the review.

• The relevant purchasing, receiving, dispensing, transfer, return, and inventory records.

• Any system activity, access records, video review, or interviews considered.

• The conclusion reached, corrective action taken, and required notifications or reports.

Not every discrepancy is diversion. It may be a legitimate count error, an unposted transaction, or a system configuration problem. But closing an issue without evidence creates risk. The record should show how the pharmacy reached its conclusion and what it changed to prevent recurrence.

Monitor dispensing patterns and system access

Dispensing data can reveal risk that a physical count alone will not. Pharmacy leadership should periodically review patterns such as frequent early refill requests, recurring cash transactions, unusually high quantities, multiple prescribers or pharmacies, unusual prescription changes, and prescriptions that appear inconsistent with the patient's profile. The purpose is not to make clinical assumptions from a single data point. It is to identify patterns that warrant pharmacist review and appropriate follow-up.

Internal monitoring matters equally. Review controlled substance dispensing, reversal, edit, override, and adjustment activity by user. Look for activity occurring outside normal workflow, repeated reversals, unusual transaction volumes, unexplained after-hours access, or one employee repeatedly associated with discrepancies. These signals do not establish wrongdoing. They establish the need for a timely, objective review.

System permissions should reflect current duties. Shared logins, generic credentials, and passwords known by multiple employees eliminate the ability to assign accountability. Every transaction involving controlled substances should be attributable to a specific authorized individual whenever the system permits it.

Train Staff to Escalate, Not to Ignore

Employees are often the first to observe a warning sign, yet many pharmacies fail to provide a clear path for reporting concerns. Training should explain not only what diversion may look like, but also what employees must do when they observe an irregularity. Staff should know who to contact, how to preserve records or evidence, and why they should not conduct informal investigations on their own.

Training is more effective when it uses pharmacy-specific scenarios. For example, staff should understand how to respond when a delivery count is short, when a controlled prescription appears altered, when a colleague asks to use another person's credentials, or when a recurring shortage cannot be explained. The goal is disciplined action, not suspicion for its own sake.

Managers also need training on escalation. A poorly handled internal inquiry can compromise evidence, create inconsistent employee treatment, or delay required reporting. Depending on the facts, the pharmacy may need to involve senior leadership, legal counsel, human resources, law enforcement, insurers, or regulatory authorities. The appropriate response depends on the nature and scope of the issue, but delay without a documented reason is rarely a sound strategy.

Test the Program Before an Inspection or Loss

A diversion program should be tested under realistic conditions. [Periodic internal audits] (https://www.veritascac.com/post/controlled-substance-audit-checklist) can evaluate whether records reconcile, personnel understand their responsibilities, access permissions remain appropriate, cameras and alarms function as intended, and discrepancy files are complete. A [mock inspection] (https://www.veritascac.com/post/mock-dea-inspection-preparation-that-works) can also reveal whether staff can retrieve required records promptly and explain their procedures consistently.

Focus audits on the points where controls commonly break down: receipt of controlled substances, inventory adjustments, returns, transfers, disposal, perpetual inventory accuracy, system access, and documentation of suspicious prescription reviews. Audit findings should produce corrective actions with assigned owners and completion dates. Repeating the same finding without escalation is evidence that oversight is not effective.

Veritas Compliance & Analytics approaches diversion prevention from an enforcement-informed perspective: the practical question is whether the pharmacy can show who was accountable, what occurred, how it was investigated, and what changed afterward. That standard should guide every policy, audit, and corrective action.

A strong diversion prevention program in not built on distrust of employees. It is built on clear expectations, consistent oversight, and documented accountability. A pharmacy that can identify, investigate, document, and correct irregularities promptly is far better positioned to protect its patients, its registration, and its business.